Cover Image
市場調查報告書

B型肝炎:開發中產品分析

Hepatitis B - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 232823
出版日期 內容資訊 英文 380 Pages
訂單完成後即時交付
價格
Back to Top
B型肝炎:開發中產品分析 Hepatitis B - Pipeline Review, H2 2017
出版日期: 2017年11月14日 內容資訊: 英文 380 Pages
簡介

B型肝炎是危險到會威脅生命的肝臟感染症。B型肝炎病毒是造成黃膽、尿液暗沈、嚴重倦怠、噁心、嘔吐、伴隨腹痛的急性疾病的原因。B型肝炎致病風險因子有年齡、嚴重的腎臟病、血友病、重覆使用的注射針頭、由感染B型肝炎的母親所生下的嬰兒等。 可用抗病毒藥物等治療。

本報告提供B型肝炎治療藥的開發情形相關調查,提供開發中產品的概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢等資訊。

簡介

B型肝炎概要

治療藥的開發

治療藥的評估

開發治療藥的企業

藥物簡介

暫停中的計劃

開發中止的產品

產品開發的里程碑

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9897IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hepatitis B - Pipeline Review, H2 2017, provides an overview of the Hepatitis B (Infectious Disease) pipeline landscape.

Hepatitis B is a potentially life-threatening liver infection caused by the hepatitis B virus. Hepatitis B virus can cause an acute illness with symptoms that last several weeks, including yellowing of the skin and eyes (jaundice), dark urine, extreme fatigue, nausea, vomiting and abdominal pain. Risk factors include age, severe kidney disease, hemophilia, share needles during drug use and born to a hepatitis-b infected mother. Treatment includes antiviral drugs.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hepatitis B - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Hepatitis B (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hepatitis B (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Hepatitis B and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 2, 7, 27, 26, 4, 64, 38 and 6 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 3, 9 and 5 molecules, respectively.

Hepatitis B (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hepatitis B (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Hepatitis B (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hepatitis B (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hepatitis B (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hepatitis B (Infectious Disease)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hepatitis B (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hepatitis B (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents 2
  • Introduction 6
  • Hepatitis B - Overview 7
  • Hepatitis B - Therapeutics Development 8
  • Hepatitis B - Therapeutics Assessment 28
  • Hepatitis B - Companies Involved in Therapeutics Development 38
  • Hepatitis B - Drug Profiles 76
  • Hepatitis B - Dormant Projects 343
  • Hepatitis B - Discontinued Products 350
  • Hepatitis B - Product Development Milestones 351
  • Appendix 360

List of Tables

  • Number of Products under Development for Hepatitis B, H2 2017 27
  • Number of Products under Development by Companies, H2 2017 29
  • Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017 30
  • Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017 31
  • Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017 32
  • Number of Products under Development by Companies, H2 2017 (Contd..4), H2 2017 33
  • Number of Products under Development by Companies, H2 2017 (Contd..5), H2 2017 34
  • Number of Products under Development by Universities/Institutes, H2 2017 35
  • Products under Development by Companies, H2 2017 36
  • Products under Development by Companies, H2 2017 (Contd..1), H2 2017 37
  • Products under Development by Companies, H2 2017 (Contd..2), H2 2017 38
  • Products under Development by Companies, H2 2017 (Contd..3), H2 2017 39
  • Products under Development by Companies, H2 2017 (Contd..4), H2 2017 40
  • Products under Development by Companies, H2 2017 (Contd..5), H2 2017 41
  • Products under Development by Companies, H2 2017 (Contd..6), H2 2017 42
  • Products under Development by Companies, H2 2017 (Contd..7), H2 2017 43
  • Products under Development by Companies, H2 2017 (Contd..8), H2 2017 44
  • Products under Development by Companies, H2 2017 (Contd..9), H2 2017 45
  • Products under Development by Universities/Institutes, H2 2017 46
  • Number of Products by Stage and Target, H2 2017 48
  • Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017 49
  • Number of Products by Stage and Mechanism of Action, H2 2017 51
  • Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017 52
  • Number of Products by Stage and Route of Administration, H2 2017 54
  • Number of Products by Stage and Molecule Type, H2 2017 56
  • Hepatitis B - Pipeline by Abivax SA, H2 2017 57
  • Hepatitis B - Pipeline by AiCuris GmbH & Co KG, H2 2017 57
  • Hepatitis B - Pipeline by AIMM Therapeutics BV, H2 2017 58
  • Hepatitis B - Pipeline by Akshaya Bio Inc, H2 2017 58
  • Hepatitis B - Pipeline by Alnylam Pharmaceuticals Inc, H2 2017 58
  • Hepatitis B - Pipeline by Altimmune Inc, H2 2017 59
  • Hepatitis B - Pipeline by Altravax Inc, H2 2017 59
  • Hepatitis B - Pipeline by Amarna Therapeutics BV, H2 2017 59
  • Hepatitis B - Pipeline by Arbutus Biopharma Corp, H2 2017 60
  • Hepatitis B - Pipeline by Arcturus Therapeutics Inc, H2 2017 61
  • Hepatitis B - Pipeline by Arrowhead Pharmaceuticals Inc, H2 2017 61
  • Hepatitis B - Pipeline by Ascentage Pharma Group Corp Ltd, H2 2017 62
  • Hepatitis B - Pipeline by Assembly Biosciences Inc, H2 2017 62
  • Hepatitis B - Pipeline by Aucta Pharmaceuticals LLC, H2 2017 63
  • Hepatitis B - Pipeline by Beijing Kawin Technology Share-Holding Co Ltd, H2 2017 63
  • Hepatitis B - Pipeline by Beijing Minhai Biotechnology Co Ltd, H2 2017 63
  • Hepatitis B - Pipeline by Benitec Biopharma Ltd, H2 2017 64
  • Hepatitis B - Pipeline by Biological E Ltd, H2 2017 64
  • Hepatitis B - Pipeline by BioStar Pharmaceuticals Inc, H2 2017 65
  • Hepatitis B - Pipeline by Bolder Biotechnology Inc, H2 2017 65
  • Hepatitis B - Pipeline by BrightGene Bio-Medical Technology Co Ltd, H2 2017 65
  • Hepatitis B - Pipeline by Bukwang Pharm Co Ltd, H2 2017 66
  • Hepatitis B - Pipeline by Cadila Healthcare Ltd, H2 2017 66
  • Hepatitis B - Pipeline by CaroGen Corp, H2 2017 67
  • Hepatitis B - Pipeline by Celltrion Inc, H2 2017 67
  • Hepatitis B - Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2017 68
  • Hepatitis B - Pipeline by Chongqing Zhifei Biological Products Co Ltd, H2 2017 68
  • Hepatitis B - Pipeline by Chromis Therapeutics Inc, H2 2017 69
  • Hepatitis B - Pipeline by Cocrystal Pharma Inc, H2 2017 69
  • Hepatitis B - Pipeline by ContraVir Pharmaceuticals Inc, H2 2017 70
  • Hepatitis B - Pipeline by CyTuVax BV, H2 2017 70
  • Hepatitis B - Pipeline by DelSiTech Oy, H2 2017 70
  • Hepatitis B - Pipeline by Dicerna Pharmaceuticals Inc, H2 2017 71
  • Hepatitis B - Pipeline by Dong-A Socio Holdings Co Ltd, H2 2017 71
  • Hepatitis B - Pipeline by Dynavax Technologies Corp, H2 2017 72
  • Hepatitis B - Pipeline by Ensemble Therapeutics Corp, H2 2017 72
  • Hepatitis B - Pipeline by Enyo Pharma SA, H2 2017 73
  • Hepatitis B - Pipeline by eTheRNA Immunotherapies NV, H2 2017 73
  • Hepatitis B - Pipeline by F. Hoffmann-La Roche Ltd, H2 2017 74
  • Hepatitis B - Pipeline by GeneCure LLC, H2 2017 74
  • Hepatitis B - Pipeline by GeoVax Labs Inc, H2 2017 75
  • Hepatitis B - Pipeline by Gilead Sciences Inc, H2 2017 75
  • Hepatitis B - Pipeline by GlaxoSmithKline Plc, H2 2017 76
  • Hepatitis B - Pipeline by Green Cross Corp, H2 2017 76
  • Hepatitis B - Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2017 77
  • Hepatitis B - Pipeline by Huons Global Co Ltd, H2 2017 77
  • Hepatitis B - Pipeline by Immunotope Inc, H2 2017 78
  • Hepatitis B - Pipeline by Indian Immunologicals Ltd, H2 2017 78
  • Hepatitis B - Pipeline by Inovio Pharmaceuticals Inc, H2 2017 78
  • Hepatitis B - Pipeline by Intellia Therapeutics Inc, H2 2017 79
  • Hepatitis B - Pipeline by Ionis Pharmaceuticals Inc, H2 2017 80
  • Hepatitis B - Pipeline by ISA Pharmaceuticals BV, H2 2017 80
  • Hepatitis B - Pipeline by Jiangsu Hansoh Pharmaceutical Group Co Ltd, H2 2017 80
  • Hepatitis B - Pipeline by Johnson & Johnson, H2 2017 81
  • Hepatitis B - Pipeline by Kineta Inc, H2 2017 81
  • Hepatitis B - Pipeline by LG Chem Ltd, H2 2017 82
  • Hepatitis B - Pipeline by Ligand Pharmaceuticals Inc, H2 2017 82
  • Hepatitis B - Pipeline by Medivir AB, H2 2017 83
  • Hepatitis B - Pipeline by Mucosis BV (Inactive), H2 2017 83
  • Hepatitis B - Pipeline by MultiCell Technologies Inc, H2 2017 84
  • Hepatitis B - Pipeline by Oncolys BioPharma Inc, H2 2017 84
  • Hepatitis B - Pipeline by Pfenex Inc, H2 2017 85
  • Hepatitis B - Pipeline by PharmaEssentia Corp, H2 2017 85
  • Hepatitis B - Pipeline by Profarma, H2 2017 86
  • Hepatitis B - Pipeline by Profectus BioSciences Inc, H2 2017 86
  • Hepatitis B - Pipeline by Qilu Pharmaceutical Co Ltd, H2 2017 86
  • Hepatitis B - Pipeline by Replicor Inc, H2 2017 87
  • Hepatitis B - Pipeline by Rodos BioTarget GmbH, H2 2017 87
  • Hepatitis B - Pipeline by Samjin Pharm Co Ltd, H2 2017 88
  • Hepatitis B - Pipeline by Sanofi, H2 2017 88
  • Hepatitis B - Pipeline by Sanofi Pasteur SA, H2 2017 89
  • Hepatitis B - Pipeline by Scynexis Inc, H2 2017 89
  • Hepatitis B - Pipeline by Shantha Biotechnics Pvt Ltd, H2 2017 89
  • Hepatitis B - Pipeline by Sinovac Biotech Ltd, H2 2017 90
  • Hepatitis B - Pipeline by Spring Bank Pharmaceuticals Inc, H2 2017 90
  • Hepatitis B - Pipeline by TCM Biotech International Corp, H2 2017 91
  • Hepatitis B - Pipeline by Theravectys SA, H2 2017 91
  • Hepatitis B - Pipeline by THEVAX Genetics Vaccine USA Inc, H2 2017 91
  • Hepatitis B - Pipeline by Transgene SA, H2 2017 92
  • Hepatitis B - Pipeline by Vaxine Pty Ltd, H2 2017 92
  • Hepatitis B - Pipeline by VBI Vaccines Inc, H2 2017 93
  • Hepatitis B - Pipeline by Vical Inc, H2 2017 93
  • Hepatitis B - Pipeline by ViroStatics srl, H2 2017 94
  • Hepatitis B - Pipeline by VLP Biotech Inc, H2 2017 94
  • Hepatitis B - Dormant Projects, H2 2017 362
  • Hepatitis B - Dormant Projects, H2 2017 (Contd..1), H2 2017 363
  • Hepatitis B - Dormant Projects, H2 2017 (Contd..2), H2 2017 364
  • Hepatitis B - Dormant Projects, H2 2017 (Contd..3), H2 2017 365
  • Hepatitis B - Dormant Projects, H2 2017 (Contd..4), H2 2017 366
  • Hepatitis B - Dormant Projects, H2 2017 (Contd..5), H2 2017 367
  • Hepatitis B - Dormant Projects, H2 2017 (Contd..6), H2 2017 368
  • Hepatitis B - Discontinued Products, H2 2017 369

List of Figures

  • Number of Products under Development for Hepatitis B, H2 2017 27
  • Number of Products under Development by Companies, H2 2017 28
  • Number of Products under Development by Universities/Institutes, H2 2017 35
  • Number of Products by Top 10 Targets, H2 2017 47
  • Number of Products by Stage and Top 10 Targets, H2 2017 47
  • Number of Products by Top 10 Mechanism of Actions, H2 2017 50
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017 50
  • Number of Products by Routes of Administration, H2 2017 53
  • Number of Products by Stage and Routes of Administration, H2 2017 53
  • Number of Products by Top 10 Molecule Types, H2 2017 55
  • Number of Products by Stage and Top 10 Molecule Types, H2 2017 55
Back to Top